Upstream Bio (UPB) Stock Price

Upstream Bio Price

NYSE·CLOSED
2.76
​
Market closed

Over the last 3 years Upstream Bio grew revenue by 33.0% annually, reaching 2.85 M USD. For Upstream Bio, the net margin of -5,026.0% is down versus -1,969.3% a few years ago.

Upstream Bio stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Upstream Bio business model & stock analysis

Upstream Bio Inc., based in Waltham, Massachusetts, is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders. The company, which went public on October 11, 2024, is advancing verekitug, a monoclonal antibody targeting TSLP, a key cytokine involved in immune-mediated conditions. It is conducting Phase II trials for severe asthma and chronic rhinosinusitis with nasal polyps, with plans to expand into COPD treatment.

Frequently asked questions about Upstream Bio

13 analysts currently rate the Upstream Bio stock: 10 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Upstream Bio to generate revenue of 2.71 M USD and earnings per share of -2.86 USD.

Converted at the current exchange rate, the Upstream Bio share trades at 2.46 EUR (2.76 USD).

The expected revenue of Upstream Bio is 2.71 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Upstream Bio is -155.35 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Upstream Bio is currently -0.96. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Upstream Bio stock.

The price-to-sales ratio (P/S) of Upstream Bio is currently 55.28. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Upstream Bio stock.

The Eulerpool Quality Score for Upstream Bio is 3/10.

The ISIN of Upstream Bio is US91678A1079. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Upstream Bio is UPB. The ticker symbol is used to trade Upstream Bio shares on the stock exchange.

Fair ValueTerminal
2.54 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
38,053.33 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Oct 11, 2024
ISIN
US91678A1079
Cusip
91678A107
Market capitalization
149.15 M USDMicro Cap
52-Week Range
PEG
-7.39
P/E ratio
P/Ee 2026
-0.96
P/Ee 2027
-1.00
P/Ee 2028
-0.96
P/Ee 2029
-0.86
P/Ee 2030
-0.96
P/Se
55.28
EV/EBIT
—
P/B Ratio
0.44
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-42.13 %
Last updated Oct 19, 2026, 7:45 AM

Upstream Bio Peer Group

All fundamentals and in-depth analysis of Upstream Bio

Our stock analysis for Upstream Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Upstream Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.